Tonix Pharmaceuticals (US:TNXP) Globenewswire·2026-03-17 20:35Core Insights - Tonix Pharmaceuticals Holding Corp. announced presentations on its preclinical immuno-oncology portfolio at the AACR Annual Meeting 2026, scheduled for April 17–22, 2026, in San Diego, California [1] Oral Presentation Details - The oral presentation titled "TFF2 deficiency amplifies IL-1β-driven inflammation and promotes aging-associated gastric tumor progression" will take place on April 21, 2026, from 2:30–4:30 p.m. PT [2] - Presenters include Shuang Li, MD, PhD, and Timothy C. Wang, MD, with Tonix co-authors Seth Lederman, MD, and Bruce L. Daugherty, PhD, MBA [2] Poster Presentation Details - The first poster presentation titled "In vitro characterization of fully human antagonistic anti-BTLA monoclonal antibodies" is scheduled for April 21, 2026, from 2:00-5:00 p.m. PT [3] - The second poster presentation titled "Pharmacokinetics of TNX-1700 in non-human primates and human FcRn/serum albumin transgenic mice" will occur on April 22, 2026, from 9:00 a.m.–12:00 p.m. PT [3] - Both presentations will be led by Bruce Daugherty, PhD, MBA [3] About TNX-1700 - TNX-1700 is a fusion protein of TFF2 and albumin, currently in preclinical development for treating gastric and colorectal cancer in combination with PD-1 blockade [4] - The drug is in the pre-Investigational New Drug (IND) stages of development and was in-licensed from Columbia University [4] Company Overview - Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments for high unmet medical needs [5] - The company’s marketed products include TONMYA for fibromyalgia, Zembrace® Symtouch® for acute migraines, and Tosymra® [5] - Tonix is also investigating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and has a pipeline including TNX-2900 for Prader-Willi syndrome and monoclonal antibodies for Lyme disease prophylaxis and kidney transplant rejection [5]